Class information for:
Level 1: TELMISARTAN//ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER//CLIN TRIAL MANAGEMENTITABASHI KU

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
10881 959 44.9 88%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
132 22818 ANGIOTENSIN II//ANGIOTENSIN 1 7//RENIN ANGIOTENSIN SYSTEM

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 TELMISARTAN Author keyword 34 21% 14% 139
2 ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER Author keyword 4 19% 2% 17
3 CLIN TRIAL MANAGEMENTITABASHI KU Address 3 100% 0% 3
4 MOL CARDIOVASC BIOL PHARMACOL Address 2 16% 1% 14
5 BIOL DEV TISSU ADIPEUXCNRSUMR 6543 Address 2 67% 0% 2
6 CNRS 6543 Address 2 67% 0% 2
7 PHARMACOLITABASHI KU Address 2 67% 0% 2
8 GENOM EPIDEMIOL CLIN TRIALSITABASHI KU Address 2 50% 0% 3
9 PPAR GAMMA ACTIVATION Author keyword 2 50% 0% 3
10 ANGIOTENSINOGEN EXPRESSION Author keyword 1 100% 0% 2

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 TELMISARTAN 34 21% 14% 139 Search TELMISARTAN Search TELMISARTAN
2 ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER 4 19% 2% 17 Search ANGIOTENSIN+II+TYPE+1+RECEPTOR+BLOCKER Search ANGIOTENSIN+II+TYPE+1+RECEPTOR+BLOCKER
3 PPAR GAMMA ACTIVATION 2 50% 0% 3 Search PPAR+GAMMA+ACTIVATION Search PPAR+GAMMA+ACTIVATION
4 ANGIOTENSINOGEN EXPRESSION 1 100% 0% 2 Search ANGIOTENSINOGEN+EXPRESSION Search ANGIOTENSINOGEN+EXPRESSION
5 PHOSPHORYLATED ALPHA SYNUCLEIN 1 50% 0% 2 Search PHOSPHORYLATED+ALPHA+SYNUCLEIN Search PHOSPHORYLATED+ALPHA+SYNUCLEIN
6 SHR SR 1 100% 0% 2 Search SHR+SR Search SHR+SR
7 ANGIOTENSIN II TYPE I RECEPTOR BLOCKER 1 25% 0% 4 Search ANGIOTENSIN+II+TYPE+I+RECEPTOR+BLOCKER Search ANGIOTENSIN+II+TYPE+I+RECEPTOR+BLOCKER
8 ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS 1 13% 1% 8 Search ANGIOTENSIN+II+TYPE+1+RECEPTOR+BLOCKERS Search ANGIOTENSIN+II+TYPE+1+RECEPTOR+BLOCKERS
9 3 UTR POLYMORPHISM 1 50% 0% 1 Search 3+UTR+POLYMORPHISM Search 3+UTR+POLYMORPHISM
10 A RETROSPECTIVE COHORT STUDY 1 50% 0% 1 Search A+RETROSPECTIVE+COHORT+STUDY Search A+RETROSPECTIVE+COHORT+STUDY

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 DECREASES ADIPOCYTE SIZE 18 89% 1% 8
2 PREADIPOSE CELLS 16 64% 2% 16
3 INCREASED ENERGY EXPENDITURE 10 33% 3% 26
4 TELMISARTAN PREVENTS 8 100% 1% 5
5 HUMAN PREADIPOCYTES 8 20% 4% 34
6 TYPE 1 RECEPTOR BLOCKERS 7 43% 1% 13
7 TELMISARTAN 6 11% 5% 48
8 TO HEAD TRIALS 6 100% 0% 4
9 FRUCTOSE FED RATS 4 22% 2% 18
10 DIFFERENTIATION SPECIFIC ELEMENT 4 56% 1% 5

Journals

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
The renin-angiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome 2012 54 117 46%
Role of adipose tissue renin-angiotensin system in metabolic and inflammatory diseases associated with obesity 2011 51 86 52%
Modulation of glucose metabolism by the renin-angiotensin-aldosterone system 2015 1 187 39%
The adipose renin-angiotensin system: Role in cardiovascular disease 2009 46 67 64%
The physiology of a local renin-angiotensin system in the pancreas 2007 67 43 70%
The renin-angiotensin system in adipose tissue and its metabolic consequences during obesity 2013 15 214 40%
The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome? 2003 202 136 38%
The renin-angiotensin-aldosterone system and glucose homeostasis 2011 36 58 40%
The adipose tissue renin-angiotensin system and metabolic disorders: a review of molecular mechanisms 2012 13 106 64%
The Role of the Renin-Angiotensin-Aldosterone System in Obesity-Related Renal Diseases 2013 12 97 30%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 CLIN TRIAL MANAGEMENTITABASHI KU 3 100% 0.3% 3
2 MOL CARDIOVASC BIOL PHARMACOL 2 16% 1.5% 14
3 BIOL DEV TISSU ADIPEUXCNRSUMR 6543 2 67% 0.2% 2
4 CNRS 6543 2 67% 0.2% 2
5 PHARMACOLITABASHI KU 2 67% 0.2% 2
6 GENOM EPIDEMIOL CLIN TRIALSITABASHI KU 2 50% 0.3% 3
7 FRANZ VOLHARD CLIN CHARITE 1 100% 0.2% 2
8 UT EXTENS FAMILY CONSUMER SCI 1 50% 0.2% 2
9 CANADA CHAIR CARDIOVASC OBES MANAGEMENT 1 33% 0.3% 3
10 OBES EDUC INITIAT 1 30% 0.3% 3

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000282347 HUMAN URINARY KALLIDINOGENASE SK 827//HYPERTENS DIABET UNIT//MUSCLE METAB
2 0.0000123611 PATOL VASC NEFROL EXPT//VASC RENAL PATHOL//MED ALFREDO LANARI
3 0.0000116656 ANGIOTENSIN 1 7//ANGIOTENSIN CONVERTING ENZYME 2//MAS RECEPTOR
4 0.0000100754 SPECIALIZED HYPERTENS GENET//HYPERTENS GENET SPECIALIZED//BIOMED IL 236
5 0.0000096689 UNITE PHARMACOEPIDEMIOL EA 3696//BLOOD POTASSIUM//HYPERGLUCAGONAEMIA
6 0.0000089721 HYPERINSULINEMIA//SUGAR INDUCED HYPERTENSION//ATHEROSCLEROSIS METAB CLIN NUTR
7 0.0000088671 CANDESARTAN CILEXETIL//ANGIOTENSIN II RECEPTOR ANTAGONIST//LOSARTAN
8 0.0000082173 AT2 RECEPTOR//COMPOUND 21//ANGIOTENSIN RECEPTORS
9 0.0000077802 ADRENAL RENIN//ANGIOTENSINOGEN//TISSUE RENIN
10 0.0000074862 ANTIDIABETIC PHARMACOTHERAPY//CHAIR GERIATR SURG//HEART FAILURE INCOR